Determine the Efficacy and Safety of Harvoni in Genotype 1 Chronic Hepatitis c Infected People Who Are Alcoholics

NCT ID: NCT02759861

Last Updated: 2023-12-29

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 16 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-08-01
• Study Completion Date: 2020-10-01

Brief Summary

To determine the efficacy and safety of Harvoni in treatment-naïve alcoholic subjects with Genotype 1 HCV infection

Detailed Description

determine the cure rate of Harvoni in treatment naïve alcoholic subjects with Genotype 1 HCV infection

Conditions

Genotype 1 Hepatitis C Virus

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Harvoni x 8 or 12 weeks

patient will receive 8 or 12 weeks depending on clinical data

Group Type: EXPERIMENTAL

harvoni

Intervention Type: DRUG

8 or 12 weeks of harvoni therapy with monthly nursing visiting to monitor alcohol and adherence of harvoni therapy

Interventions

harvoni

8 or 12 weeks of harvoni therapy with monthly nursing visiting to monitor alcohol and adherence of harvoni therapy

Intervention Type: DRUG

Other Intervention Names

Ledipasvir/Sofosbuvir

Eligibility Criteria

Inclusion Criteria

1. The subject must be willingly and able to provide written informed consent

2. Age 19 years of age or older (The age of consent in Nebraska)

3. HCV treatment-naïve, as defined as no prior exposure to any Interferon (IFN), RBV, or other FDA approved or experimental HCV-specific direct-acting antiviral agent

4. HCV RNA level at most 6 months prior to the Baseline/Day 1 visit.

5. HCV genotyping 1a, 1b, or mixed 1a/ab. Any non-definitive results will exclude the subject from study participation.

6. Alcohol misuse as defined by the Alcohol Use Disorders Identification Test (AUDIT) score subjects must score > 8 (associated with harmful or hazardous drinking)

7. Cirrhosis determination [up to 20% of study subjects may have cirrhosis]:

1. Cirrhosis is defined as any one of the following:

• History of a liver biopsy showing cirrhosis (e.g. Metavir score = 4 or Ishak score > 5)
• Fibroscan showing cirrhosis or results > 12.5 kPa
• FIBRO Spect II index consistent with F3 or F4 AND an AST : platelet ration index (APRI) of > 2 during Screening

2. Absence of cirrhosis is defined as any one of the following:

• Liver biopsy within 2 years of Screening showing absence of cirrhosis
• Fibroscan within 6 months of Baseline/Day1 with a result of ≤ 12.5 kPa
• FIBRO Spect II Index consistent with F0- F2 AND APRI of ≤ 1 during Screening

8. Liver imaging within 6 months of Baseline/Day 1 to exclude hepatocellular carcinoma HCC) is required

9. Subjects must have the following laboratory parameters at screening:

1. ALT < 10 x the upper limit of normal (ULN)

2. AST < 10 x ULN

3. Direct bilirubin < 2.0 x ULN

4. Platelets > 50,000

5. HbA1c < 8.5%

6. Creatinine clearance (CLcr) ≥ 60 mL /min, as calculated by the Cockcroft-Gault equation

7. Hemoglobin ≥ 11 g/dL for female subjects; ≥ 12 g/dL for male subjects.

8. Albumin ≥ 2.5 g/dL

9. INR ≤ 1.5 x ULN unless subject has known hemophilia or is stable on an anticoagulant regimen affecting INR.

10. Subject has not been treated with any investigational drug or device within 30 days of the screening visit.

Exclusion Criteria

1. Pregnant women and nursing mothers are ineligible due to the possible risk of adverse effects in the newborn. Eligible patients of reproductive potential should use adequate contraception if sexually active.

2. Serious concurrent medical illness which would jeopardize the ability of the subject to receive the therapy as outlined in this protocol with reasonable safety.

3. Malignancy diagnosed or treated within 5 years (recent localized treatment of squamous or non-invasive basal cell skin cancers is permitted; cervical carcinoma in situ is allowed if appropriately treated prior to screening); subjects under evaluation for a malignancy are not eligible.

4. Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)

5. Use of any prohibited concomitant medications within 30 days of the Baseline/Day 1 visit.

6. Known hypersensitivity to LDV/SOF

• Minimum Eligible Age: 19 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Nebraska

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Mark Mailliard, MD

Role: PRINCIPAL_INVESTIGATOR

UNMC

Locations

University of Nebraska

Omaha, Nebraska, United States

Countries

United States

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

0121-16-FB

Identifier Type: -

Identifier Source: org_study_id